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Endocrine therapyAbstract Background: Recent data have raised concern about the clinical efﬁcacy of aroma-
tase inhibitors in overweight and/or obese breast cancer patients. We report in vivo aromatase
inhibition and plasma and tissue oestrogen levels in relation to body mass index (BMI) status
among breast cancer patients treated with different aromatase inhibitors.
Methods: We compared data on in vivo aromatase inhibition (64 patients) as well as plasma
and tissue oestrogen levels from patients participating in our studies to BMI values.
Results: We found a weak positive correlation between pretreatment aromatisation level and
BMI (n = 64; R = 0.236; p = 0.060) but no correlation between on-treatment aromatisation
levels or percentage aromatase inhibition and BMI within patient subgroups treated with
any of a panel of aromatase inhibitors. Pre-treatment levels of plasma estradiol (p < 0.001),
estrone (p = 0.001) and estrone sulphate (p = 0.002) correlated to BMI. While on-treatment
levels of plasma estrane sulphate correlated to BMI in patients on letrozole (R = 0.601;
p = 0.001; n = 25 for all) or anastrozole (n = 12; R = 0.611; p = 0.035) therapy, letrozole sup-
pressed plasma estrone sulphate more than anastrozole independent of BMI. No correlation
between on-treatment tumour oestrogen levels and BMI was recorded.el.: +47
1056 P.E. Lønning et al. / European Journal of Cancer 50 (2014) 1055–1064Conclusions: Our unique data do not support a lack of effective aromatase inhibition in over-
weight patients or therefore a need for alternative therapy. The higher levels of estrogens in
overweight postmenopausal breast cancer patients before and during aromatase inhibition
may be due to effects of BMI on oestrogen metabolism rather than aromatisation.
 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. 1. Introduction
Obesity is associated with a signiﬁcantly elevated
breast cancer risk [1] and a poor breast cancer prognosis
in postmenopausal women [2]. While the mechanisms
are not fully understood, the fact that obesity has been
associated with elevated plasma estradiol levels [3,4], a
known risk factor for postmenopausal breast cancer
[1], has suggested elevated estradiol (E2) could be partly
responsible for these eﬀects.
Aromatase inhibitors, applied as either mono-
therapy or sequentially to tamoxifen have become
standard adjuvant endocrine therapy for postmeno-
pausal women [5]. However, conﬂicting evidence has
questioned the beneﬁt of aromatase inhibitors in over-
weight/obese patients. In the Austrian ABCSG-12 trial
randomising premenopausal breast cancer patients
between treatment with goserelin plus either tamoxifen
or anastrozole, Pfeiler and colleagues found a signiﬁ-
cantly higher relapse rate among overweight premeno-
pausal women treated with zoladex plus anastrozole as
compared to those treated with zoladex with tamoxi-
fen [6]. In the ATAC study, Sestak et al. [7] found
women with a BMI >35 to have a poor prognosis
compared to lean women independent of treatment
arm (tamoxifen versus anastrozole); however, there
was a non-signiﬁcant trend indicating a reduced bene-
ﬁt for anastrozole as compared to tamoxifen among
obese individuals. In contrast, analysing data from
the BIG 1–98 study, Ewertz et al. [8] found the beneﬁt
for letrozole as compared to tamoxifen to be indepen-
dent of BMI value.
Importantly, clinical superiority for aromatase inhib-
itors versus tamoxifen has been shown for the so-called
third-generation compounds; anastrozole, exemestane
and letrozole. In contrast, ﬁrst- and second-generation
aromatase inhibitors like aminoglutethimide, 4-
hydroxyandrostenedione and fadrozole revealed
anti-tumour eﬃcacy resembling but not superior to the
eﬃcacy of conventional therapies [9]. While ﬁrst-and
second-generation aromatase inhibitors reduce in vivo
aromatisation by 70–90% [9], anastrozole, exemestane
and letrozole each inhibit in vivo aromatisation by
>98% [10–12]. These data indicate a dose–response rela-
tionship between the degree of aromatase inhibition and
anti-tumour eﬃcacy related to treatment with aromatase
inhibitors [13]; thus, even a moderate increase in oestro-
gen levels among overweight patients may potentially
reduce the eﬃcacy of aromatase inhibitors.While postmenopausal estrogens are synthesised by
peripheral aromatisation, plasma levels may be inﬂu-
enced by several factors, like androgen substrate level
and oestrogen clearance rate [14]. Thus, it is of impor-
tance to directly determine in vivo aromatase inhibition
in overweight patients treated with aromatase inhibitors.
Here, we took the opportunity to determine potential
correlations between BMI and the level of in vivo aroma-
tisation, assessed by in vivo tracer injections, prior to
commencing on and during treatment with diﬀerent aro-
matase inhibitors. For this purpose, we included all
patients participating in our previous tracer studies for
whom data on BMI were available. In addition, we cor-
related BMI to plasma and tissue oestrogen levels before
treatment and during therapy with the third-generation
non-steroidal compounds letrozole and anastrozole, and
to androgen levels in a cohort of healthy postmeno-
pausal women.
2. Methods
2.1. Studying eﬀect of BMI on in vivo aromatisation
An overview of patients included from diﬀerent previ-
ous studies is presented in Table 1.
To evaluate potential correlation between in vivo aro-
matisation of androstenedione into estrone and BMI, we
obtained data from six trials [11,12,15–18] enrolling a
total of 64 patients. As for the on-therapy data, due to
the fact that diﬀerent aromatase inhibitors express dif-
ferent potency, on-treatment data obtained on each aro-
matase inhibitor were analysed separately. In addition,
data obtained during treatment with exemestane [11]
and during treatment with anastrozole from the cross-
over study [12] were pooled, considering these two drugs
to be of similar biochemical eﬃcacy. On the contrary,
we did not analyse data obtained on letrozole treatment
in the same patients crossing-over between anastrozole
and letrozole [12]. The main reason for this was the fact
that all patients obtained aromatase inhibition >99.1%,
the formal detection limit of the assay, during letrozole
treatment.
The protocol for aromatase assessment was identical
in all the studies. In brief, each patient received a bolus
injection of [3H] androstenedione (500 l CI) and
[14C]estrone (5 l CI) dissolved in 8% ethanol (W/W)
followed by 96 h of urine collection. The percentage aro-
matisation was calculated from the 3H/14C isotope ratio
in the oestrogen metabolites in the urine.
Table 1
Diﬀerent studies providing material for the analysis performed here.
No Body mass index (BMI) range Setting Drug treatment Parameter addressed Reference
In vivo aromatisation
10 19.5–42.0 Metastatic Exemestane Pre/on treat % aromatisation [11]
12 18.3–32.5 Metastatic Anastrozole* Pre/on treat % aromatisation [12]
7 19.5–34.9 Metastatic Aminoglutethimide (AG) Pre/on treat % aromatisation [18]
5 13.9–29.4 Metastatic Rogletimide Pre/on treat % aromatisation [18]
7 20.3–32.7 Metastatic i.m. 4-OHA Pre/on treat % aromatisation [15]
10 23.5–32.0 Metastatic i.m. 4-OHA + AG Pre/on treat % aromatisation [17]
13 20.4–35.6 Metastatic Oral 4-OHA Pre-treat*** % aromatisation [16]
Plasma oestrogen levels
12 18.3–32.5 Metastatic Anastrozole Pre/on treat plasma oestrogen levels [20]**
12 18.3–32.5 Metastatic Letrozole Pre/on treat plasma oestrogen levels [20]**
13 22.3–37.2 Primary Letrozole Pre/on treat plasma oestrogen levels [20]
Tissue oestrogen levels
13 22.3–37.2 Primary Letrozole Pre/on treat tissue oestrogen levels [20]
* Cross-over study in which patients were crossed over between anastrozole and letrozole. Because all patients obtained aromatase inhibition below
detection limit on letrozole (>99.1% inhibition), only on-treatment data on anastrozole are used for BMI correlations.
** The plasma oestrogen values presented here are based on re-analysis of samples obtained from reference 12 with the novel improved radio-
immunoassay described.
*** Only pretreatment levels are used for BMI comparison. The reason for this is that 4-OHA administered by the oral route is an insuﬃcient
aromatase inhibitor; thus, to correlate on-treatment aromatisation to BMI may be misleading. 4-OHA = 4-hydroxyandrostenedione.
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Over the years, our radioimmunoassays for plasma
oestrogen analysis have gradually been improved aiming
at obtaining the lowest sensitivity limits. Thus, for the
purpose of the analysis presented here, only plasma
oestrogen levels analysed by our most recently devel-
oped methods [19] were used. As for samples collected
from studies conducted prior to implementation of this
technique [12], these plasma samples had all been re-
analysed as part of a later study [20] using our novel
assay [19]. In brief, 3H-labelled estrone, estradiol and
estrone sulphate (about 2000 dpm each) were added to
plasma samples (2 mL) as internal recovery standards.
Unconjugated estrogens (estrone and estradiol) were
removed by ether extraction followed by chromato-
graphic separation on LH-20 columns using dichloro-
methane: ethyl acetate: methanol (97:5:1 by vol) as
solvent. Estradiol was analysed using 125I-estradiol
(estradiol-6-(O-carboxymethyl)-oximino-2-(2-[125I]-iodo-
histamine) with a speciﬁc activity of about 2000 Ci/
mmol as tracer and the ER 150 (Sorin Biomedica) anti-
body. To obtain maximum sensitivity, estrone, follow-
ing separation, was converted into estradiol [21] and
analysed according to the same procedure as for
estradiol.
Subsequent to extraction of the unconjugated estro-
gens, ethanol was added to the residual water fraction.
Conjugated estrogens were extracted, and estrone sul-
phate hydrolysed into unconjugated estrone with use of
the S-9754 sulphatase enzyme followed by extraction,
column puriﬁcation, conversion into estradiol and radio-
immunoassay as described above. Final values for each
of the estrogens were corrected for procedural loss
through assessing the amount of 3H-labelled compoundin each fraction (estradiol, estrone and estrone sulphate
separately), and ﬁnal values corrected for the amount
of 3H-labelled steroid included. Detection limits for
plasma estradiol, estrone and estrone sulphate were
0.67, 1.14 and 0.55 pmol/L, respectively.
To correlate plasma oestrogen levels to BMI, we used
plasma oestrogen levels from a study [20] evaluating
plasma and tissue oestrogen levels before and during
letrozole administered as primary medical therapy for
locally advanced breast cancer (Table 1). In addition,
samples obtained from the patients during treatment
with letrozole or anastrozole from the 2002 cross-over
study [12] were re-analysed with our novel assay [19]
in 2008 [20]. As data from both studies were analysed
in parallel, we found it feasible to combine pretreatment
plasma estrogen levels from the two data sets for BMI
correlation analysis. As letrozole and anastrozole have
been shown to diﬀer with respect to potency as in vivo
aromatase inhibitors [12], oestrogen levels during treat-
ment with either anastrozole or letrozole were correlated
with BMI separately.
2.3. Breast cancer tissue oestrogen levels and BMI
To compare potential correlation between BMI and
breast cancer oestrogen levels before and during treat-
ment, data from the 13 patients [20] treated with letroz-
ole from whom breast cancer tissue was collected prior
to commencing treatment and at surgery after 3 months
on letrozole therapy were available.
2.4. Plasma androgen levels in respect to BMI
Finally, to look for potential correlations between
plasma androgen and BMI levels, we compared plasma
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healthy women previously reported [22].
2.5. Ethical considerations
Each individual study was conducted in accordance
with the Helsinki declaration and approved by the
Ethics Committee at the Royal Marsden Hospital or
the regional ethics committee at the University of Bergen.
All patients provided written informed consent to
participate in these studies.2.6. Statistical analysis
Previous work by our group has shown plasma oestro-
gen and androgen levels in postmenopausal women to be
well ﬁtted to a lognormal distribution [23]. Thus, all hor-
mone values and percentage aromatisation were analysed
after lognormal transformation. Statistical analysis was
conducted with use of the SPSS version 20.0 software.
R-values were calculated according to the Spearman for-
mula, and all p-values are reported as two-tailed.3. Results
3.1. In vivo aromatisation and BMI
Combining the results from the six tracer studies
(Table 1 and Fig. 1a), a non-signiﬁcant correlation
between BMI and the pre-treatment percentage aroma-
tisation was observed (n = 64; R = 0.236; p = 0.060).
Excluding the single outlier with a BMI of 42.0 slightly
improved the correlation (n = 63; R = 0.281; p = 0.026).
Correlation between on-treatment percentage aroma-
tisation during treatment with the diﬀerent compounds
and BMI is presented individually in Fig. 1b–h with
their respective R- and p-values. As may be observed,
no signiﬁcant correlation between on-treatment aroma-
tisation values and BMI was recorded. In addition, no
correlation between BMI and individual percentage aro-
matase inhibition was observed (data not shown).3.2. Plasma oestrogen levels and BMI
Pretreatment plasma oestrogen levels in relation to
BMI are shown in Fig. 2a–c. We detected statistical sig-
niﬁcant correlations between BMI and pre-treatment
plasma levels of E2 (R = 0.757; p < 0.001), E1
(R = 0.628; p = 0.001) and E1S (R = 0.590; p = 0.002);
in addition, on-treatment values of plasma E1S during
treatment with letrozole (Fig. 3a) as well as during treat-
ment with anastrozole (Fig. 3b) correlated to BMI as well
(n = 25; R = 0.601; p = 0.001 and n = 12; R = 0.611;
p = 0.035). Notably, plasma levels of E1S during anas-
trozole treatment were higher as compared to values on
letrozole (Fig. 3b and c) independent of BMI.3.3. Intratumour tissue oestrogen levels and BMI
Intratumour tissue levels of E2, E1 and E1S before and
during treatment with letrozole are depicted in Fig. 4a–c.
While we observed a positive albeit non-signiﬁcant corre-
lation between pretreatment intratumour levels of E1
(R = 0.451, p = 0.12) and BMI, no correlation between
BMI and intratumour levels of E2 or E1S or on-treatment
levels of any of the estrogens was recorded.3.4. Plasma androgen levels and BMI
In postmenopausal women, estrogens are synthesised
in diﬀerent body compartments from plasma androgens
taken up from the circulation [14]. No correlation
between either plasma levels of androstenedione
(R = 0.006; p > 0.4) or testosterone (R = –0.142;
p > 0.10) and BMI was recorded, excluding elevated
androgen precursor levels as a potential cause of ele-
vated oestrogen levels in overweight women.4. Discussion
Previous studies by our groups [23–26] as well as oth-
ers [1] have revealed positive correlations between
plasma and/or normal breast tissue oestrogen levels
and BMI. Using highly sensitive radioimmunoassays
[19], we conﬁrmed a signiﬁcant association between
plasma levels of E2 as well as E1 and E1S and BMI in
patients prior to commencing endocrine treatment. In
addition, we found a signiﬁcant correlation between
on-treatment levels of plasma E1S and BMI during
treatment with the third-generation aromatase inhibi-
tors letrozole but also anastrozole. A potential correla-
tion between on-treatment levels of plasma E1 and E2
during treatment and BMI could not be addressed due
to the fact that 22 and 18 out of a total of 25 patients
revealed plasma E2 and E1 levels below detection limit
on letrozole treatment, respectively. With anastrozole,
ﬁve out of 12 patients revealed plasma E2 levels below
the detection limit. For patients treated with exemes-
tane, pre- and on-treatment plasma oestrogen levels
had to be analysed by a special procedure including
pre-puriﬁcation with use of HPLC due to cross-contam-
ination from drug metabolites in conventional radioim-
munoassays [27]. Accordingly, these results could not be
pooled with results from other studies for joint analysis.
To the best of our knowledge, two previous studies
only have addressed plasma oestrogen levels in relation
to BMI in patients on treatment with an aromatase
inhibitor. In a previous study, some of us [26] revealed
low E2 and E1S levels in patients during treatment with
aromatase inhibition; yet, there was a positive correla-
tion between on-treatment plasma levels of E2 as well
as E1S and BMI during treatment with letrozole and a
non-signiﬁcant trend during anastrozole therapy. For
Fig. 1. In vivo aromatisation in relation to body mass index (BMI) before treatment with diﬀerent aromatase inhibitors (pooled data; a) and during
therapy with anastrozole (b), exemestane (c), aminoglutethimide (AG) (d), 4-hydroxy androstenedione (4OHA) 500 mg i.m. (e), 4-hydroxy
androstenedione 250 mg i.m. (f), AG and 4OHA in combination (g) and rogletimide (h). Correlation lines are drawn based on log-normal
distribution of the data.
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levels were higher on anastrozole as compared to onletrozole treatment. These ﬁndings resemble the results
reported here. In contrast, Diorio and colleagues [28]
Fig. 2. Plasma oestrogen levels before treatment with anastrozole or
letrozole based on data from Ref. [20] including data from Ref. [12]
reanalysed and presented in [20] in relation to body mass index (BMI).
(a) plasma estradiol, (b) plasma estrone and (c) estrone sulphate.
Correlation lines are drawn based on log-normal distribution of the
data.
Fig. 3. Plasma levels of E1S (obtained from Ref. [20] including data
from Ref. [12] reanalysed and presented in Ref. [20]) during treatment
with non-steroidal third-generation aromatase inhibitors in relation to
body mass index (BMI). (a) pooled data (n = 25) during treatment
with letrozole; (b) during treatment with anastrozole (n = 12; patients
originally presented in reference [12]) and (c); data from the same
individuals as reported in b during treatment with letrozole. Note that
for each individual patient plasma E1S suppression was more profound
during letrozole as compared to during anastrozole treatment inde-
pendent of BMI status. Correlation lines are drawn based on log-
normal distribution of the data.
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levels and BMI. While most patients in their study
revealed low concentrations of E2 during treatment, sev-
eral patients in their study revealed plasma levels of
estradiol exceeding 10 pg/ml (37 pM) or, even,
20 pg/ml, values rarely observed with use of sensitive
radioimmunoassays in any of our laboratories. The
study by Diorio et al. also included a limited number
of patients treated with exemestane; for these patients,the potential of cross-reactive metabolites in the radio-
immunoassay should be considered [27].
Our ﬁnding of a weak, borderline signiﬁcant correla-
tion between pre-treatment aromatisation levels and
BMI is consistent with previous observations recorded
Fig. 4. Tumour tissue oestrogen levels before and during treatment with letrozole [25]. (a) estradiol, (b) estrone, and (c) estrone sulphate.
Correlation lines are drawn based on log-normal distribution of the data.
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Contrary to expectations, for patients treated with
potent third-generation inhibitors we found a non-sig-niﬁcant negative correlation between on-treatment per-
centage aromatisation and BMI (Fig. 1), consistent
with a non-signiﬁcant positive correlation between
1062 P.E. Lønning et al. / European Journal of Cancer 50 (2014) 1055–1064percentage aromatase inhibition and BMI. While these
moderate correlations may have occurred by chance,
our ﬁndings argue against a hypothesis indicating lack
of eﬀective aromatase inhibition in overweight patients.
This argument is further substantiated by the fact that
all 13 patients investigated for in vivo aromatase inhibi-
tion on treatment with letrozole had total body aroma-
tisation inhibited by >99.1% [12], which is the sensitivity
limit of the assay.
An issue of controversy has been the potential role of
local breast or breast cancer oestrogen production versus
systemic delivery to intratumour oestrogen levels. While
there is evidence in favour of elevated local breast aroma-
tisation with obesity [29], recent studies by our groups
[25,30,31] indicate local production may have limited
eﬀect on tissue oestrogen levels due to rapid equilibrium
between plasma and tissue compartments. Rather, the
reason for elevated tissue compared to plasma levels
for E1 and E2 relates to lipophilicity of the steroidal com-
pounds [32]. In addition, tumour E2 levels may increase
due to local ER binding [30]. Taken together, our ﬁnding
of a positive correlation between intra-tumour pretreat-
ment E1 but not E2 or E1S to BMI is consistent with these
previous observations. Similar, our ﬁnding of a non-sig-
niﬁcant negative correlation between each tumour oest-
rogen fraction (E2, E1 and E1S) and BMI during
aromatase inhibitor treatment argues against the
hypothesis that obesity may be associated with elevated
local oestrogen synthesis escaping aromatase inhibition.
While the ﬁndings in this study are consistent with a
hypothesis indicating a moderate correlation between
in vivo total body aromatisation and BMI, notably,
plasma oestrogen levels are inﬂuenced by multiple fac-
tors in addition to degree of aromatisation. While we
recorded no correlation between androgen precursor
levels and BMI, variation in other parameters, including
oestrogen metabolism, may contribute. Estrogens are
metabolised by multiple CYPs in the liver inﬂuenced
by exogenous as well as endogenous compounds, prob-
ably obesity as well [33–38].
The ﬁndings in this study provide information of clin-
ical importance. First, our data provide no support for a
positive correlation between residual in vivo aromatisa-
tion and BMI in patients on treatment with either a sec-
ond-generation or a third-generation aromatase
inhibitor. Second, plasma but also tissue oestrogen val-
ues detected during therapy were extremely low in all
patients, arguing against systemic as well as local failure
of aromatase inhibitors in overweight/obese patient.
Third, as for patients treated sequentially with anastroz-
ole and letrozole, letrozole consistently caused better
plasma E1S suppression as compared to anastrozole
independent of BMI levels.
Previously, we found letrozole to be superior com-
pared to anastrozole with respect to tissue oestrogen
suppression as well [20]. While the aromatase inhibitormetaanalysis [5] did not reveal any preference for any
of the three third-generation compounds (anastrozole,
letrozole and exemestane), the ﬁndings presented here,
in concert with the endocrine ﬁndings from the ALI-
QUOT study [26,39] and the clinical data of Pfeiler [6]
and Sestak [7] argue for caution with respect to use of
anastrozole and potential preference for letrozole in
overweight and obese patients.
The negative impact of obesity recorded in the Aus-
trian ABCSG 12 trial [6] was substantially stronger than
what was observed in the ATAC study. There may be
several potential explanations to these ﬁndings. Aroma-
tase inhibitors, in contrast to tamoxifen, are ineﬀective
in patients with any residual ovarian function [40]; thus,
the data from the Austrian study raise the worrying ques-
tion whether these ﬁndings may be due to zoladex failure
in obese breast cancer patients. Notably, treatment with
aromatase inhibitors may trigger the hypophyseal–gona-
dal axis [40]. Until more data are available, we suggest
regular endocrine monitoring of all obese patients to be
treated with an LHRH analogue with or without con-
comitant treatment with an aromatase inhibitor. As for
such a purpose, direct radioimmunoassays that are able
to discriminate between pre- and postmenopausal status,
in concert with FSH and LH monitoring, may provide a
crude assessment. To evaluate optimal suppression dur-
ing treatment with an LHRH analogue and an aroma-
tase inhibitor in concert, would require highly sensitive
assays currently available for research purposes only.
However, we believe studies evaluating oestrogen sup-
pression in response to such combined treatment to be
a signiﬁcant priority, and blood samples for oestrogen
analysis should be collected from such studies.
In conclusion, our unique data do not support a lack
of eﬀective aromatase inhibition in overweight patients
or therefore a need for alternative therapy. The higher
levels of estrogens in overweight postmenopausal breast
cancer patients before and during aromatase inhibition
may be due to eﬀects of BMI on oestrogen metabolism
rather than aromatisation.
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